FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 702 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ¿Es seguro el CBD para las personas con cáncer? August 19, 2021 Medicare Open Enrollment Starts Tomorrow! October 14, 2021 FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer July 4, 2025 Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds July 22, 2019 Load more HOT NEWS Returning to Dental Care Immunotherapy Effective in Alveolar Soft Part Sarcoma Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments...
